Review highlights variability in dry eye disease rates among immune checkpoint inhibitor users

Dry eye disease (DED) occurs in about 2% of patients treated with immune checkpoint inhibitors (ICIs), according to a study that found most cases are mild and manageable with topical treatment. Across 13 studies, the pooled incidence of DED among patients receiving ICIs was 2%. However, reported rates varied widely...